论文部分内容阅读
目的对慢性心力衰竭并发肺部感染治疗中应用头孢哌酮舒巴坦的临床疗效进行分析。方法选取本院于2011年4月~2013年9月收治慢性心力衰竭并发肺部感染患者62例,随机分为两组,对照组30例给予头孢曲松钠治疗,观察组32例给予头孢哌酮舒巴坦治疗,对比两组治疗效果、细菌清除率与不良反应发生情况。结果观察组治疗总有效率与细菌清除率显著高于对照组,不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论头孢哌酮舒巴坦在慢性心力衰竭并发肺部感染治疗中可发挥显著疗效,可有效清除致病菌,大幅提高患者生活质量,值得在临床中推广。
Objective To analyze the clinical efficacy of cefoperazone sulbactam in the treatment of pulmonary heart disease complicated with chronic heart failure. Methods From April 2011 to September 2013, 62 patients with chronic heart failure complicated with pulmonary infection were selected and randomly divided into two groups. In the control group, 30 patients were treated with ceftriaxone sodium. In the observation group, 32 patients were given cefoperazone Ketosis sulbactam treatment, compared the two groups of treatment, bacterial clearance rate and adverse reactions. Results The total effective rate and bacterial clearance in the observation group were significantly higher than those in the control group, and the incidence of adverse reactions was significantly lower than that in the control group (P <0.05). Conclusion Cefoperazone sulbactam can play a significant role in the treatment of chronic heart failure complicated by pulmonary infection, which can effectively remove pathogenic bacteria and greatly improve the quality of life of patients. It is worth to be popularized clinically.